# Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

> **NCT05176483** · PHASE1 · RECRUITING · sponsor: **Exelixis** · enrollment: 1314 (estimated)

## Conditions studied

- Renal Cell Carcinoma (RCC)
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Urothelial Carcinoma (UC)
- Solid Tumor
- Hepatocellular Carcinoma (HCC)
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Clear Cell Renal Cell Carcinoma (ccRCC)
- Non-Clear Cell Renal Cell Carcinoma (nccRCC)

## Interventions

- **DRUG:** Zanzalintinib
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Nivolumab
- **DRUG:** Nivolumab + Relatlimab

## Key facts

- **NCT ID:** NCT05176483
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-14
- **Primary completion:** 2030-06-28
- **Final completion:** 2030-06-28
- **Target enrollment:** 1314 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05176483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05176483, "Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05176483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*